Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pegasys

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. [Pg.354]

These detection techniques have found heavy planets with up to 400 Earth-mass but are unlikely to detect Earth-mass planets because the Doppler shift is too small. The first extrasolar planet to be discovered by the Doppler variation technique was 51-Pegasi, with the results shown in Figure 7.9. Precise radial... [Pg.207]

Figure 7.9 Doppler profile for 51-Pegasi. (Reproduced by permission of Sylvain Korzennik, Harvard-Smithsonian Center for Astrophysics)... Figure 7.9 Doppler profile for 51-Pegasi. (Reproduced by permission of Sylvain Korzennik, Harvard-Smithsonian Center for Astrophysics)...
Current extrasolar planets are all much larger than the Earth. The total count at present (9 September 2005) is 168 found in 144 planetary systems, of which 18 contain multiple planets. The first to be discovered was 51-Pegasi in the constellation of Pegasus by the radial velocity method. It is about 0.45 Mjupiter and has an orbital period around the star of about 4.5 days. Of the 168 planets found so far only nine are present within a habitable zone around their star. The survey of the star catalogue for planets has only just started and we have found a large number of planets very quickly - solar systems, at least, are not special. [Pg.209]

Two PEG-IFNs are available, Pegasys and PEG-Intron (Table 25-9). It is unclear which is superior. [Pg.294]

Pegasys, PEG IFN a-2a Hoffman-La Roche, Inc. Chronic hepatitis C in patients not previously treated with IFN-a Combination therapy with Ribavirin Combination therapy with Copegus Oct. 2002 Dec. 2002 Feb. 2005... [Pg.150]

Interferon-a Hepatitis B and C Pegasys, Peg-Intron, Ribetron, Copegus... [Pg.96]

Interferon. (Source Roche. Pegasys improves things for patients with chronic hepatitis C. http //www.roche.coin/pages/facets/10/pegasyse.htm [accessed November 2, 2007]. Used with permission.)... [Pg.116]

Pegasys (PEGinterferon a-2a, produced in E. coli) Hoffman-La Roche Hepatitis C 2002 (EU, USA)... [Pg.503]

Peginterferon alfa-2a (pegylated interferon alfa-2a, Pegasys)... [Pg.1089]

PEGASYS (peginterferon Roche Liquid single-dose... [Pg.325]

In the case of u Sgr Hack and Pasinetti (1963) derived, from a comparison with Y Pegasi, a B2 IV (Hoffleit and Jaschek 1982), that He is 40 times more abundant than H. U Sgr does not appear to show a Balmer discontinuity. [Pg.200]

Peginterferon a-2a/ Pegasys Biological response modifier Roche sc 84% 94 mL/h 80 (50-140) h... [Pg.21]

A. Gibas N.E. Martin, M.L. Shiffman, and L.S. Marsano. 2000. The pharmacokinetic behaviour of pegylated (40 kDa) interferon alfa-2a (Pegasys) in chronic hepatitis C patients after multiple dosing. Hepatology 32 394A. [Pg.293]

Pegasys PEG-interferon alpha Roche Chronic hepatitis 2002... [Pg.69]

See other pages where Pegasys is mentioned: [Pg.233]    [Pg.240]    [Pg.356]    [Pg.121]    [Pg.129]    [Pg.208]    [Pg.224]    [Pg.294]    [Pg.14]    [Pg.158]    [Pg.213]    [Pg.1980]    [Pg.249]    [Pg.76]    [Pg.177]    [Pg.209]    [Pg.945]    [Pg.166]    [Pg.515]    [Pg.135]    [Pg.249]    [Pg.348]    [Pg.293]    [Pg.403]    [Pg.439]   
See also in sourсe #XX -- [ Pg.224 ]

See also in sourсe #XX -- [ Pg.209 , Pg.503 ]

See also in sourсe #XX -- [ Pg.945 , Pg.946 ]

See also in sourсe #XX -- [ Pg.166 ]

See also in sourсe #XX -- [ Pg.123 ]

See also in sourсe #XX -- [ Pg.40 ]

See also in sourсe #XX -- [ Pg.565 ]



SEARCH



51-Pegasi

51-Pegasi

PEGASYS (peginterferon alfa

© 2024 chempedia.info